SCHEMBL1759620

SCHEMBL1759620

[CH2]C(O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.46
ALDH1A1 P00352 3/20 0.45
MAPT P10636 3/20 0.44
EPHX2 P34913 1/20 0.44
TOP2A P11388 1/20 0.40
TOP2B Q02880 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KDM4E B2RXH2 1/20 0.40
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
MAOB P27338 1/20 0.38
AOC3 Q16853 1/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
BLM P54132 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HIF1A Q16665 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16771224 0.83 PDE2A (0.49) PDE2AALDH1A1MAPTEPHX2TOP2A
SCHEMBL646362 0.83 TOP2A (0.49) PDE2AALDH1A1MAPTEPHX2TOP2A
SCHEMBL8848833 0.79 PDE2A (0.46) PDE2AALDH1A1MAPTEPHX2TOP2A
SCHEMBL18291828 0.79 PDE2A (0.54) PDE2AALDH1A1MAPTEPHX2TOP2A
SCHEMBL1046494 0.79 PDE2A (0.54) PDE2AALDH1A1MAPTEPHX2TOP2A
SCHEMBL5924733 0.79 PDE2A (0.54) PDE2AALDH1A1MAPTEPHX2L3MBTL1
SCHEMBL16563637 0.79 PDE2A (0.42) PDE2AALDH1A1MAPTEPHX2TOP2A
SCHEMBL27763932 0.77 CETP (0.46)
SCHEMBL254957 0.76 MAPT (0.56) PDE2AALDH1A1MAPTEPHX2L3MBTL1
SCHEMBL23149869 0.76 PDE2A (0.44) PDE2AALDH1A1MAPTEPHX2TOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2501685-A1 [1,5]-DIAZOCIN DERIVATIVES Mellitech (FR) 2012-09-26 EP claimed
US-20120225892-A1 [1,5]-Diazocin Derivatives MELLITECH (FR) 2012-09-06 US claimed
WO-2011058193-A1 [1,5]-DIAZOCIN DERIVATIVES MELLITECH (FR) 2011-05-19 WO claimed
US-8765728-B2 [1,5]-diazocin derivatives MELLITECH (FR) 2014-07-01 US disclosed
EP-2501685-A1 [1,5]-DIAZOCIN DERIVATIVES Mellitech (FR) 2012-09-26 EP disclosed
US-20120225892-A1 [1,5]-Diazocin Derivatives MELLITECH (FR) 2012-09-06 US disclosed
WO-2011058193-A1 [1,5]-DIAZOCIN DERIVATIVES MELLITECH (FR) 2011-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225892-A1 [1,5]-Diazocin Derivatives IAPP, INSR, GLP1R PDE2A 422/4885ALDH1A1 610/4885MAPT 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.